Evidence outlook
Approved: Rheumatoid Arthritis, COVID-19
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (5)
- Giant Cell Arteritis (GCA) TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of giant cell arteritis (GCA) in adult patients.
- Polyarticular Juvenile Idiopathic Arthritis (PJIA) TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
- Cytokine Release Syndrome (CRS) TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome in adults and pediatric patients 2 years of age and older.
- Patients 2 years of age and older with active systemic juvenile idiopathic arthritis
- Tocilizumab STADA (previously Tofidence), biosimilar of RoActemra: rheumatoid arthritis (moderate to severe active RA after DMARDs or TNF blockers; severe progressive RA not previously treated with methotrexate), systemic juvenile idiopathic arthritis, juvenile idiopathic polyarthritis, and COVID-19 in adults on systemic corticosteroids who need oxygen or ventilation.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03830203 NCT03830203 · Rheumatoid Arthritis The study was randomized, quadruple-blind, and actively controlled with EU-licensed Actemra, enrolling 621 participants; its primary endpoint was the clinical ACR20 response at 6 months. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Registry: NCT03830203 | 3 | Percentage of Participants With an American College of Rheumatology 20 Percent (%) (ACR20) Response (6 months) 2021-01-05 | ACR20 response rate at week 24: 67.9% reference tocilizumab vs 69.9% BAT1806/BIIB800; treatment difference 1.9% (90% CI -4.0 to 7.9), within predefined equivalence margins | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other IL-6 receptor drugs
Sarilumab, tocilizumab, Levilimab. Compare all 4 IL-6 receptor drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for COVID-19: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| BAT1806 (Tofidence): this drug | Approved | Monoclonal antibody | IL-6 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| CT-P47 (tocilizumab) (Avtozma) | Approved | Monoclonal antibody | IL-6R antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Elasomeran (Spikevax) | Approved | Vaccine | SARS-CoV-2 spike protein | Reliable signal | No reviewed efficacy summary in this indication | |
| Tocilizumab (Actemra / RoActemra) | Approved | Monoclonal antibody | IL-6 receptor | Partial signal | NCT04409262: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 (Up to Day 28): Remdesivir + Placebo (RDV+Placebo) - mITT Population 14 days (95% CI 11 to 16) | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population 14 days (95% CI 12 to 15) missed NCT04372186: Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 (Up to Day 28): Tocilizumab 12.04 Percentage of Participants (95% CI 8.52 to 16.86) | Placebo 19.26 Percentage of Participants (95% CI 13.34 to 27.36) | |
| Azvudine (FNC) | Phase 3 | Small molecule | HIV reverse transcriptase | not yet graded | No reviewed efficacy summary in this indication | |
| Ibuzatrelvir | Phase 3 | Small molecule | SARS-CoV-2 3CL protease | not yet graded | No reviewed efficacy summary in this indication | |
| Levilimab (Ilsira) | Phase 3 | Monoclonal antibody | IL-6 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Masitinib | Phase 2 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | not yet graded | No reviewed efficacy summary in this indication | |
| GSK4396687 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.